BioNTech (NASDAQ: BNTX) director reports direct and indirect share holdings

Rhea-AI Filing Summary

BioNTech SE director Helmut Wolfgang Jeggle reported his initial ownership of the company’s ordinary shares. The Form 3 shows he holds 332,316 ordinary shares directly and 656,951 ordinary shares indirectly as of March 18, 2026. The indirect shares are held by Salvia GmbH, where he serves as Chief Executive Officer and may be deemed to beneficially own the shares held by that entity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jeggle Helmut Wolfgang

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	332,316	D
Ordinary Shares	656,951	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Salvia GmbH. The Reporting Person is the Chief Executive Officer of Salvia GmbH and may be deemed to beneficially own the ordinary shares held by Salvia GmbH.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

How many BioNTech (BNTX) shares does Helmut Jeggle hold directly?

Helmut Wolfgang Jeggle holds 332,316 BioNTech ordinary shares directly. This direct position is reported on his Form 3 as of March 18, 2026, reflecting his personal ownership stake separate from any entity-controlled or indirect holdings disclosed.

What are Helmut Jeggle’s indirect BioNTech (BNTX) share holdings?

Jeggle is reported as indirectly holding 656,951 BioNTech ordinary shares. These shares are held by Salvia GmbH, where he is Chief Executive Officer and may be deemed to beneficially own the ordinary shares that entity holds, according to the filing footnote.

What does BioNTech’s Form 3 disclose about Salvia GmbH’s holdings?

The Form 3 states that Salvia GmbH holds BioNTech ordinary shares, totaling 656,951 attributed as indirect holdings. Helmut Jeggle, as Chief Executive Officer of Salvia GmbH, may be deemed to beneficially own the ordinary shares held by that company under SEC beneficial ownership rules.

Is Helmut Jeggle a director, officer, or major shareholder of BioNTech (BNTX)?

Helmut Wolfgang Jeggle is identified as a director of BioNTech SE in the Form 3. He is not listed as an officer and is not flagged as a ten percent owner in this filing, which focuses on his reported direct and indirect share ownership.

Does the BioNTech (BNTX) Form 3 show any recent share purchases or sales?

The Form 3 functions as an initial ownership report and shows only holdings entries. It lists Jeggle’s direct and indirect ordinary share positions without indicating any specific buy or sell transactions, focusing solely on shares beneficially owned as of the reported date.